Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients
M. Milano(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Luca Valenti(University of Milan), Stefano Romeo(Sahlgrenska University Hospital), Anna Ludovica Fracanzani(University of Milan), Massimo Colombo(University of Milan), Raffaele De Francesco(University of Milan), Marco Maggioni(University of Milan), Felix Stickel(University Hospital of Zurich), Janett Fischer(Leipzig University), Roberta D’Ambrosio(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alessio Aghemo, Jochen Hampe(Else Kröner-Fresenius-Stiftung), Thomas Berg(Leipzig University of Applied Sciences), Silvia Fargion(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Rosellina Margherita Mancina(Università Campus Bio-Medico), Paola Dongiovanni(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Stella De Nicola(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 58
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877